Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alpha interferon clinical trial for multiple sclerosis: design considerations.

M Alter, J Greenstein, D Camenga

    Neuroepidemiology
    |January 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy" [Eur. J. Pharmacol. 991 (2025) 177310].

    European journal of pharmacology·2025
    Same author

    [Hidradenitis suppurativa].

    Dermatologie (Heidelberg, Germany)·2024
    Same author

    [How I do… oocyte retrieval with locoregional anesthesia of parameters under vaginal ultrasound].

    Gynecologie, obstetrique, fertilite & senologie·2022
    Same author

    [Cutaneous squamous cell carcinoma].

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2020
    Same author

    Using X-rays in photodynamic therapy: an overview.

    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2018
    Same author

    Epidermal melanocytes in segmental vitiligo show altered expression of E-cadherin, but not P-cadherin.

    The British journal of dermatology·2018

    Alpha-2 interferon did not benefit patients with multiple sclerosis (MS) in a placebo-controlled trial. The study found no significant impact on the disease

    Area of Science:

    • Neurology
    • Immunology
    • Clinical Trials

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Interferons have been explored as potential treatments for MS, with varying results.
    • Alpha-2 interferon is a specific type of interferon investigated for its immunomodulatory effects.

    Purpose of the Study:

    • To evaluate the efficacy of alpha-2 interferon in treating patients with multiple sclerosis.
    • To assess the safety and tolerability of alpha-2 interferon in the MS patient population.
    • To compare the clinical course of MS in patients receiving alpha-2 interferon versus placebo.

    Main Methods:

    • A placebo-controlled clinical trial design was employed.
    • Patients diagnosed with multiple sclerosis were enrolled.

    Related Experiment Videos

  • Treatment allocation involved either alpha-2 interferon or a placebo.
  • The course of the disease was monitored over the trial duration.

    • Main Results:

    • No statistically significant beneficial effect of alpha-2 interferon on the course of multiple sclerosis was observed.
    • The interferon treatment did not demonstrate a positive impact on disease progression or symptoms.
    • The study concluded that alpha-2 interferon is not effective for managing MS.

    Conclusions:

    • Alpha-2 interferon does not appear to be an effective therapeutic agent for multiple sclerosis.
    • Further research may be needed to explore other interferon subtypes or treatment strategies for MS.
    • The findings contribute to understanding the limited role of alpha-2 interferon in MS management.